Focal injury and worn cartilage: why the distinction matters

When a patient arrives at clinic asking whether ChondroFiller injection is right for their knee, the answer rarely turns on symptom severity alone. It turns on geometry — specifically, on the structural condition of the cartilage surrounding the damage.

Two very different clinical pictures can produce similar pain and swelling. A sports collision, awkward fall, or twisting injury typically punches a contained cavity into otherwise healthy cartilage — a focal defect with defined edges and, crucially, an intact cartilage rim around it. Wear-and-tear osteoarthritis works differently: it erodes cartilage progressively and diffusely, so there are no clean edges and no preserved surrounding border to speak of.

That distinction matters because ChondroFiller injection is fundamentally a regenerative scaffold treatment. The collagen scaffold is placed into the defect and the patient's own cells migrate in to rebuild tissue over the following months. For that process to work as intended, the surrounding cartilage rim must be healthy enough to contain and anchor the scaffold — a structural prerequisite that a focal post-traumatic defect is far more likely to provide than a joint worn down by years of degenerative change.

In wear-and-tear osteoarthritis, where those structural conditions are absent, ChondroFiller injection can still play a role — but the goal shifts from tissue regeneration to cushioning and joint protection. The mechanism is the same; the clinical target, and therefore the expected outcome, is different.

Understanding which picture applies is the right question to bring to assessment — not simply 'can I have this injection?' but 'does the pattern of damage in my knee match what this treatment is designed to do?'

What a post-traumatic focal defect actually looks like

A focal cartilage defect has a distinctive anatomy. Whether caused by a direct blow to the knee, a twisting fall, or the gradual bone-cartilage separation seen in osteochondritis dissecans (OCD), the result is a localised, crater-like lesion concentrated in one area — with the surrounding joint surface remaining largely intact. On ICRS grading, the lesions that sit within ChondroFiller injection's primary evidence base are Grade 3 (extending more than 50% through cartilage depth) and Grade 4 (penetrating through to subchondral bone). Think of it as a pothole in an otherwise sound road: the damage is real and contained, but the surface around it is still structurally in good order.

Defect size is a meaningful variable in treatment selection. Lesions up to approximately 3 cm² sit squarely within ChondroFiller injection territory — with additional dosing extending that range to around 6 cm² for larger or multi-compartment presentations. This places them in a distinct bracket from the very smallest defects (under 2 cm²) historically managed by microfracture, and from the larger or more complex lesions where cell-based procedures such as MACI or fresh osteochondral allograft (OCA) become the more appropriate choice.

Timing carries clinical weight here. Acute intra-articular injury sets off an inflammatory biological response — including a mitochondrial-ROS cascade — that, left unaddressed, can drive progressive joint-wide degradation. A focal defect does not inevitably stay focal. OCD, which presents with the same bounded geometry, is a specifically cited population alongside post-traumatic lesions in the published ChondroFiller injection evidence base — an important reminder that the structural picture, rather than the cause of injury alone, is what determines suitability.

How ChondroFiller injection works in a focal defect

The treatment itself takes place in an outpatient clinic setting. Under real-time ultrasound guidance, the ChondroFiller injection delivers an acellular collagen scaffold directly into the lesion — no arthroscopy, no general anaesthetic, and no operating theatre. The scaffold fills the defect volume to flush with the surrounding cartilage surface, establishing the physical conditions for the body's own repair process to take over.

That repair process is matrix-induced chondrogenesis. Progenitor cells from the local tissue migrate into the collagen scaffold and, over the following months, progressively rebuild cartilage from the base of the defect upward — a 'bottom-up' restoration. Because the scaffold sits within the contained geometry of a post-traumatic lesion (the structural picture described in the preceding sections), cell migration is channelled inward rather than dissipated across a wider joint surface.

Dosing is proportional to defect size. Most focal defects in this population are managed with a single injection; larger or multi-compartment presentations may call for two or three boxes of scaffold material. The incremental dosing reflects the same geometric logic — more volume to fill, more scaffold required.

Reaching a defect without arthroscopic access also has practical significance. Conventional surgical cartilage procedures require a dry joint environment and arthroscopic visualisation; ChondroFiller injection requires neither. Patients who are not suitable for theatre-based repair, or who want to avoid the additional biological disruption that intra-articular surgery can itself introduce, can still access a regenerative pathway — one grounded in the same structural prerequisites that post-traumatic focal defects are particularly well placed to provide.

How wear-and-tear OA changes ChondroFiller's role

Wear-and-tear osteoarthritis presents a different biological problem — and one that changes what ChondroFiller injection can reasonably be asked to do.

In diffuse OA (Kellgren-Lawrence Grade III or IV), cartilage loss spreads across broader joint surfaces without concentrating in a single bounded area. Without a discrete cavity to fill, ChondroFiller injection is applied instead as a 'top-down' additive layer: coating degenerated bone surfaces with a viscoelastic collagen cushion to absorb friction and provide joint protection. The treatment goal shifts to pain reduction and joint preservation rather than tissue regeneration — a difference in mechanism and intent, not quality of care.

Combining ChondroFiller injection with Arthrosamid

For KL Grade III/IV, a dual-injection protocol pairs ChondroFiller injection (2.3 mL applied to the bone surfaces) with Arthrosamid (6 mL applied to the synovium). These are two separate products addressing different structures in the same joint, not a single blended treatment: ChondroFiller provides the collagen cushioning layer on degenerating bone ends, while Arthrosamid — a non-regenerative polyacrylamide hydrogel — targets the synovial lining to reduce pain signalling and improve the joint fluid environment. In the most severe presentations, autologous mesenchymal stem cells may be added as a third component, sourced from bone marrow, fat tissue, or ear cartilage.

Being 'bone on bone' on imaging does not automatically exclude a patient from assessment. However, where KL Grade IV changes are accompanied by mechanical failure, significant deformity, or symptoms that have not responded to a structured joint-preservation programme, total knee replacement becomes the more appropriate next step rather than further additive treatment.

Candidacy criteria: the practical differences between the two groups

Separating these two populations in practice comes down to three overlapping variables: the condition of the cartilage surrounding the defect, the geometry of the damage, and timing — assessed through clinical examination, weight-bearing imaging, and a structured review of treatment goals.

As the preceding sections have established, the health of the surrounding cartilage border is the pivotal structural prerequisite — more so than symptom severity or patient age alone. Where that border is intact and the lesion is geometrically contained at ICRS Grade 3 or 4, the conditions for regenerative ChondroFiller injection are most likely to be met. Where diffuse wear-and-tear OA has eroded those borders across wider joint surfaces, the goal shifts to the OA cushioning pathway described in the previous section.

Defect size then determines where ChondroFiller injection sits alongside other restorative options in the post-traumatic group. Lesions under 2 cm² may suit microfracture or osteochondral autograft (OATS); between 2 and 10 cm², cell-based surgical procedures such as MACI and ACI become relevant alternatives; and for larger or structurally complex post-traumatic presentations where autograft volume is insufficient, fresh osteochondral allograft (OCA) covers a single-stage surgical route. ChondroFiller injection — as an outpatient, ultrasound-guided scaffold pathway — sits alongside these options for suitable focal defects, particularly where surgical candidacy is limited.

Timing acts as a third variable. Earlier assessment after acute injury, before the inflammatory process outlined in the previous sections drives broader joint degradation, preserves more structural prerequisites for regeneration. Where lower-limb malalignment is loading the damaged compartment, osteotomy to correct the mechanical axis may be considered as a mechanical adjunct to any cartilage pathway — a brief but clinically meaningful addition to the candidacy assessment.

None of these variables are self-assessed. Candidacy across the full range of options is determined through clinical review, full imaging, and a frank conversation about what each pathway can realistically achieve.

Outcomes: what the evidence shows and what to realistically expect

Published data from over 19,000 ChondroFiller® injection cases globally — drawn predominantly from post-traumatic focal defect and osteochondritis dissecans cohorts — report IKDC score improvements of approximately +30 points. The IKDC (International Knee Documentation Committee) score is a patient-reported measure of knee symptoms and function on a 0–100 scale; a gain of around 30 points crosses the threshold considered clinically meaningful. On MRI, MOCART scores — which assess the degree and quality of defect fill on imaging — reach the 70–87 range, indicating good-to-near-complete filling of the treated lesion.

No head-to-head randomised controlled trial has directly compared outcomes in post-traumatic and primary OA cohorts treated with ChondroFiller injection; the evidence base is observational and multi-centre in design. Individual results also vary with defect size, surrounding tissue biology, activity level, and the joint environment at the time of treatment. Long-term durability data beyond standard follow-up windows remains limited across cartilage repair modalities generally.

The recorded complaint rate of approximately 0.06% across the published case volume points to a favourable safety profile — relevant context for any patient weighing the risk-benefit balance at the decision stage.

Taken together, the evidence suggests that ChondroFiller injection delivers its strongest regenerative results when the structural prerequisites described throughout this article are in place: a contained lesion, an intact surrounding border, and an otherwise preserved joint environment. Those conditions are most reliably met in the post-traumatic focal defect group, which is why patient selection — rather than the treatment in isolation — does most of the predictive work.

1. [1] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351
2. [2] Post-traumatic arthritis. https://en.wikipedia.org/?curid=56957582 https://en.wikipedia.org/?curid=56957582